enGene Therapeutics Inc. Warrants
ENGNW$0.24 0.00 (0.00%)
Company News
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
Junshi Biosciences announced that China's NMPA has accepted new drug applications for JS001sc, a subcutaneous formulation of toripalimab (anti-PD-1 monoclonal antibody), across 12 tumor indications. The Phase 3 clinical trial demonstrated non-inferior drug exposure and comparable efficacy and safety compared to intravenous administration, marking...
